|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nabriva Therapeutics AG (NBRV) |
|
|
$0.39 0.00 (0.00%) as of 4:30 Wed 12/2
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
150,780,000 |
| Market
Cap: |
59.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3938 - $0.3938 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
51,839 |
| Total Sell Value |
$0 |
$0 |
$0 |
$9,588 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-18 |
4 |
S |
$11.16 |
$131,880 |
D/D |
(11,822) |
2,624,633 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-13 |
4 |
S |
$11.13 |
$122,232 |
D/D |
(10,984) |
2,636,455 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-12 |
4 |
S |
$11.22 |
$148,653 |
D/D |
(13,250) |
2,647,439 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-11 |
4 |
S |
$11.40 |
$98,034 |
D/D |
(8,597) |
2,660,689 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-10 |
4/A |
S |
$10.73 |
$406,451 |
D/D |
(37,876) |
2,669,286 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-10 |
4 |
S |
$10.73 |
$406,451 |
D/D |
(37,876) |
185,394 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-07 |
4/A |
S |
$10.96 |
$235,931 |
D/D |
(21,501) |
2,707,162 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-07 |
4 |
S |
$10.96 |
$235,931 |
D/D |
(21,501) |
223,270 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-06 |
4/A |
S |
$11.20 |
$350,160 |
D/D |
(31,217) |
2,728,663 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-04-06 |
4 |
S |
$11.20 |
$350,160 |
D/D |
(31,217) |
244,771 |
|
- |
|
| Talbot George Harrison |
Director |
– • – |
2017-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,235 |
4,084 |
|
- |
|
| Vivo Capital Viii, Llc |
10% Owner |
– – • |
2017-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
194,170 |
|
- |
|
| Vivo Capital Viii, Llc |
10% Owner |
– – • |
2017-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,079,860 |
|
- |
|
| Sender Gary |
Chief Financial OfficerOfficer |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
220 |
|
- |
|
| Wolf John Peter Iii |
General Counsel and Corp. Sec. |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
270 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
391,960 |
|
- |
|
| Broom Colin Md |
Chief Executive OfficerOfficer |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,582 |
|
- |
|
| Broom Colin Md |
Chief Executive OfficerOfficer |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
159 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
275,988 |
|
- |
|
| Khuong Chau Quang |
Director |
– • • |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
391,960 |
|
- |
|
| Talbot George Harrison |
Director |
– • – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,849 |
|
- |
|
| Gelone Steven P. |
Chief Development OfficerOffic |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,274 |
|
- |
|
| Seltzer Elyse G. |
Chief Medical OfficerOfficer |
• – – |
2016-12-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
240 |
|
- |
|
323 Records found
|
|
Page 13 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
